Will any new partnerships, licensing deals, or strategic collaborations be announced at the conference?

Based on the information you’ve provided, the only details disclosed about the upcoming Canaccord Genuity 45th Annual Growth Conference are that Stoke Therapeutics’ interim CEO, Ian F. Smith, will be presenting. The announcement does not mention any new partnerships, licensing agreements, or strategic collaborations that will be revealed at the event.

What this means for you

Why a definitive answer isn’t possible

• The press release focuses solely on the presentation at the conference and the company’s lead investigational medicine (zorevunersen) for Dravet syndrome.
• No mention is made of any upcoming or planned collaborations, licensing deals, or strategic partnerships in the release.
• Unless the company issues a separate statement or the conference presentation itself includes such announcements (which cannot be known ahead of time), we can only state that no such information has been disclosed.

What you can do next

1. Monitor the conference – If you need definitive confirmation, watch the live presentation or any follow‑up press releases that come out after the conference.
2. Check company filings – Shortly after the conference, Stoke Therapeutics may file a Form 8‑K or issue a news release that would detail any new agreements.
3. Set up alerts – Set a news or SEC‑filing alert for “Stoke Therapeutics” and “STOK” so you’ll be notified promptly if any partnership or licensing deal is announced.

Until an official statement is released, we cannot confirm that any new partnerships, licensing deals, or strategic collaborations will be announced at the event.